Description

Brentuximab is a targeted monoclonal antibody-drug conjugate (ADC) designed for specific therapeutic applications. Its primary value lies in its precision in targeting and delivering a cytotoxic agent directly to cells expressing the CD30 antigen, minimizing off-target effects. This makes it a critical component in advanced pharmaceutical research and development, particularly for oncology-focused applications. Industries requiring high-purity, research-grade biologics for drug discovery, clinical trials, and biopharmaceutical manufacturing are the key users of this compound.

Application

• Primary active pharmaceutical ingredient (API) in the formulation of targeted cancer therapeutics.
• Critical reference standard for bioanalytical method development and validation in pharmacokinetic studies.
• Key reagent in biomedical research investigating CD30-positive malignancies, such as Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
• Essential component for the quality control and stability testing of ADC-based drug products.
• Used in preclinical studies to evaluate efficacy, toxicity, and mechanism of action.
• Vital material for the development and calibration of diagnostic assays targeting the CD30 biomarker.

Basic Information

Product Name	Brentuximab
CAS No.	914088-09-8
Molecular Formula	C6474H10012N1724O2016S44
Molecular Weight	~151.8 kDa
Synonyms	Brentuximab Vedotin; Adcetris®; Anti-CD30 ADC; cAC10-vcMMAE; SGN-35; Monoclonal Antibody cAC10 Conjugated with MMAE; Anti-CD30 Monoclonal Antibody-Monomethyl Auristatin E Conjugate
EINECS	Contact for details

Quality Control

Our Brentuximab is manufactured and tested under strict quality systems to ensure it meets the high standards required for research and pharmaceutical development. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing critical quality attributes such as purity, potency, aggregation, and endotoxin levels. We adhere to relevant cGMP guidelines where applicable to support our clients' regulatory submissions.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store at -20°C or below. This product is hygroscopic (moisture-sensitive) and should be handled under controlled, dry conditions to prevent degradation. Allow the product to equilibrate to room temperature before opening to minimize moisture condensation.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or solid
Identification (HPLC/MS)	Conforms to reference standard
Purity (SEC-HPLC)	≥ 95.0% (Monomer)
Protein Content (UV)	90.0% - 110.0% of label claim
Drug-to-Antibody Ratio (DAR)	3.5 - 4.5 (by HPLC)
Potency (Cell-based assay)	Contact for details
Endotoxin	< 10 EU/mg
Residual Moisture (KF)	< 5.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.